000			02218 a2200577 4500
005			20250515053938.0
264		0	_c20070510
008			200705s 0 0 eng d
022			_a0007-1188
024	7		_a10.1038/sj.bjp.0707132 _2doi
040			_aNLM _beng _cNLM
100	1		_aKukreja, R C
245	0	0	_aCardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. _h[electronic resource]
260			_bBritish journal of pharmacology _cMar 2007
300			_a538-40 p. _bdigital
500			_aPublication Type: Comment; Journal Article; Research Support, N.I.H., Extramural
650	0	4	_a3',5'-Cyclic-GMP Phosphodiesterases _xantagonists & inhibitors
650	0	4	_aAnimals
650	0	4	_aAntihypertensive Agents _xpharmacology
650	0	4	_aCarbolines _xpharmacology
650	0	4	_aCardiomyopathies _xchemically induced
650	0	4	_aCardiovascular Agents _xpharmacology
650	0	4	_aCyclic Nucleotide Phosphodiesterases, Type 5
650	0	4	_aDisease Models, Animal
650	0	4	_aDoxorubicin
650	0	4	_aEndothelium, Vascular _xdrug effects
650	0	4	_aEnzyme Inhibitors
650	0	4	_aErectile Dysfunction _xdrug therapy
650	0	4	_aHeart Failure _xdrug therapy
650	0	4	_aHumans
650	0	4	_aHypertension _xchemically induced
650	0	4	_aHypertension, Pulmonary _xdrug therapy
650	0	4	_aImidazoles _xpharmacology
650	0	4	_aMale
650	0	4	_aMyocardial Infarction _xdrug therapy
650	0	4	_aMyocardial Reperfusion Injury _xchemically induced
650	0	4	_aNG-Nitroarginine Methyl Ester
650	0	4	_aNitric Oxide _xmetabolism
650	0	4	_aPhosphodiesterase Inhibitors _xpharmacology
650	0	4	_aPiperazines _xpharmacology
650	0	4	_aPurines _xpharmacology
650	0	4	_aSildenafil Citrate
650	0	4	_aSulfones _xpharmacology
650	0	4	_aTadalafil
650	0	4	_aTriazines _xpharmacology
650	0	4	_aVardenafil Dihydrochloride
650	0	4	_aVasodilator Agents _xpharmacology
650	0	4	_aVentricular Remodeling _xdrug effects
773	0		_tBritish journal of pharmacology _gvol. 150 _gno. 5 _gp. 538-40
856	4	0	_uhttps://doi.org/10.1038/sj.bjp.0707132 _zAvailable from publisher's website
999			_c16808524 _d16808524